Device Trial Radar · NCT00386542
Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children
Last checked: Nov 20, 2026Latest source record: Aug 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
450
Actual
Start
Oct 2006
Primary completion
Nov 2009
Study completion May 2010
Sponsor
- Lead sponsor
- Pedro MoroFederal agency
- Sponsor type
- Federal agency
- Collaborators
- Fundación Dominicana de Infectología, Santo Domingo, Dominican Republic; Hospital Infantil Dr. Robert Reid Cabral; World Health Organization; Pan American Health Organization; PATH; Bioject Medical Technologies, Inc.; MCM Vaccines B.V.
- First posted
- Oct 11, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 6 months, up to 24 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a sequential phase I and II, controlled, double-blinded study to determine whether immune responses suggesting protection against influenza can safely be induced in young children by two reduced doses one month apart of 0.1 mL of a trivalent inactivated influenza vaccine (INF) administered by the intradermal (ID) route with an investigational ID spacer on a United States (U.S.)-licensed needle-free jet injector (JI), compared to two standard intramuscular (IM) 0.25 mL doses by needle-syringe (N-S) in this age group. The locale is a developing country where financial restraints for the use of full-dose influenza vaccine would limit protection from an influenza pandemic threat, where N-Ss pose dangers and drawbacks in clinical use, and where Mantoux-type N-S ID injections are difficult to administer during mass campaigns.
Conditions
- Influenza
Interventions
Vaxigrip® trivalent inactivated influenza vaccineBiological
See full description elsewhere in this record.
Intradermal spacer on Biojector® 2000 jet injectorDevice
See elsewhere in this record for full description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rates of seroconversion (SC) on HI assay 1 month after dose 2. SC defined as titer >= 40 among initial-seronegatives (titer < 8 on day 0); OR, a followup titer which rises >= 4-fold.Time frame: One month after each of doses 1 and 2.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital Infantíl Dr. Robert Reid Cabral
Santo Domingo, Nacional, Dominican Republic
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.